Not sure if drawing in the SOC and our Target lines will help the interpretation but it should:-
Keeping in mind that this data is from July and not many months on from the last readout in March of this year. The additional data provides two main significances - namely that only one new patient was recruited in that timespan but that all patients in the trial gained another 4 mths on PTX-100 since between the two readouts. Interesting to see that one of the patients previously on the highest dose seems to now be on the lowest and deriving stable disease.
PTX Price at posting:
5.6¢ Sentiment: Buy Disclosure: Held
